The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.

Latest news and blogs

Blog |
UK medicines investment: the case for improving the UK commercial environment

News |
The UK risks undervaluing life sciences manufacturing investment

News |
Accelerated review of VPAG concludes without agreement

News |
Modernising UK homecare will boost neighbourhood health services and save money, says ABPI
Best practice guidance: Supporting patient organisations to report industry funding
Transparency is essential when pharmaceutical companies work with patient organisations. This updated guidance is aimed at supporting that transparency.

Guidance for conferences and events in the UK: ABPI Code of Practice requirements
This clarifies the ABPI Code requirements for conferences and events, helps all relevant stakeholders operate in a Code-compliant, professional and ethical manner.

2024 ABPI Code of Practice – new resources
The PMCPA has published new webinars and e-learning to aid understanding of the 2024 ABPI Code of Practice.

Lives Lived Well
From patients and their loved ones to those working within the pharmaceutical industry in the UK, we share a common goal: Lives Lived Well.

Events

NICE/DSU/ABPI masterclass – Methods for the analysis of non-randomised, patient level data for the estimation of treatment effects

Save the date - ABPI Industry Summit 2025

ABPI Annual Conference 2026
ABPI’s flagship annual conference will be taking place in Central London on 23 April 2026.

UK tumbles down global rankings for pharma investment and research
A new Pharmaceutical Competitiveness Framework reveals that the UK is losing the race for investment in R&D, clinical trial delivery, and foreign direct investment, due to increasing drags on competitiveness.
Key facts and figures for the pharmaceutical industry in the UK
£46.7bn
Turnover [6]
£9bn
investment in UK R&D (more than UKRI’s entire annual budget) [3]
£17.6bn
direct Gross Value Added (GVA) [1]